Suchen
OKYO Pharma Ltd
OKYOZur Watchlist hinzufügen
1.560USD
+0.040+2.63%
Handelsschluss 08-17 16:00（ET）Kurse um 15 Minuten verzögert
79.77MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OKYO Pharma Ltd Unternehmen
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO Pharma Ltd Profil
BörsenkürzelOKYO
Name des UnternehmensOKYO Pharma Ltd
IPO-datumJul 17, 2018
CEOJacob (Gary S)
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeJul 17
AddresseFloor 4, 14/15 Conduit St
StadtLONDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlW1S 2XJ
Telefon442074952379
Websitehttps://okyopharma.com/
BörsenkürzelOKYO
IPO-datumJul 17, 2018
CEOJacob (Gary S)
Führungskräfte von OKYO Pharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
--
-100.00%
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von OKYO Pharma Ltd?
Die fünf größten Anteilseigner von OKYO Pharma Ltd sind: Dr. Raj Patil
Wie viele Institutionen halten Anteile an OKYO Pharma Ltd (OKYO)?
Mit Stand vom 2026Q1 halten 19 Institutionen Anteile an OKYO Pharma Ltd, mit einem Gesamtmarktwert von etwa 4.78M, was 9.11% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1185385.00 gestiegen.